Theravia
Private Company
Total funding raised: $13.8M
Overview
Theravia is a private, commercial-stage biopharmaceutical company with a targeted focus on rare and neglected diseases, particularly sickle cell disease. With over 20 years of collective experience from its predecessor entities, the company has established a commercial footprint in over 35 countries, treating more than 15,000 patients. Its strategy centers on in-licensing, developing, and marketing specialized therapies, supported by a partnership-driven model to build its pipeline and expand global access.
Technology Platform
Partnership-driven in-licensing and commercialization platform for rare disease therapies.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Theravia competes with large pharmaceutical companies with rare disease divisions, specialized orphan drug biotechs, and other niche commercial players. Its differentiation lies in its focused partnership model and international commercial reach for neglected subsets of rare diseases, but it must contend with well-resourced competitors advancing next-generation therapies.